Pomalidomide as an Immune-enhancing Agent for the Control of HIV

This study tests whether pomalidomide — a drug normally used for multiple myeloma — can boost the immune system's ability to control HIV in people who are already on effective antiretroviral (HIV) treatment. Participants will eventually undergo a supervised treatment interruption to see how well their immune system controls the virus. **You may be eligible if...** - You are between 18 and 70 years old with confirmed HIV-1 infection - You have been on the same antiretroviral therapy (ART) regimen for at least 4 weeks and on ART overall for at least 1 year - Your HIV viral load has been undetectable for over 1 year - Your CD4 cell count (immune cell count) is above 500 - You are willing to temporarily stop HIV treatment during the study's second phase **You may NOT be eligible if...** - Your HIV is not well controlled or recently changed regimens - You are pregnant, planning pregnancy, or breastfeeding - You have conditions that make you unable to safely stop ART Talk to your doctor to see if this trial is right for you.